Edition:
United Kingdom

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

12.14USD
14 Dec 2017
Change (% chg)

$0.15 (+1.25%)
Prev Close
$11.99
Open
$12.08
Day's High
$12.57
Day's Low
$12.02
Volume
481,259
Avg. Vol
670,619
52-wk High
$17.47
52-wk Low
$7.64

Latest Key Developments (Source: Significant Developments)

MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - MiMedx Group Inc ::MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $0.45 TO $0.50 EXCLUDING ITEMS.SEES FY 2018 GAAP EARNINGS PER SHARE $0.30 TO $0.35.SEES FY 2018 REVENUE $383 MILLION TO $387 MILLION.FY2018 EARNINGS PER SHARE VIEW $0.43 -- THOMSON REUTERS I/B/E/S.  Full Article

MiMedx Says It Expects To Exceed Top End Of Q4 Revenue Guidance Of $88 Mln
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Mimedx Group Inc ::MIMEDX ANNOUNCES EXPECTATION TO EXCEED TOP END OF FOURTH QUARTER REVENUE GUIDANCE OF $88 MILLION.SEES Q4 2017 REVENUE MORE THAN $88 MILLION.Q4 REVENUE VIEW $88.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Mimedx provides update on its reimbursement coverage
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Mimedx Group Inc :Mimedx provides update on its reimbursement coverage.Mimedx Group Inc - ‍provided a reimbursement update in light of FDA final and draft guidance documents related to human tissue​.Mimedx Group Inc - "‍with issuance of final hct/p guidance document by FDA, we believe payer coverage for epifix will further improve"​.  Full Article

MiMedx Group sees FY 2017 revenue $320.6 million to $321.6 million
Friday, 17 Nov 2017 

Nov 17 (Reuters) - MiMedx Group Inc :Sees q4 2017 revenue $87 million to $88 million.Sees FY 2017 revenue $320.6 million to $321.6 million.MiMedx Group Inc - ‍reiterates Q4 and full year 2017 guidance​.FY2017 earnings per share view $0.33, revenue view $321.5 million -- Thomson Reuters I/B/E/S.  Full Article

MiMedx group says agreed to lawsuit settlement with Halo Wound Solutions
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - MiMedx Group Inc ::Agreed to confidential settlement of lawsuit co filed against BioResolutions LLC d/b/a Halo Wound Solutions and one of Halo executives​.In addition to an undisclosed monetary settlement, other settlement terms were reached related to lawsuit with Halo Wound Solutions​.  Full Article

MiMedx announces Q3 2017 results
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Mimedx Group Inc :MiMedx announces record results for third quarter of 2017 and raises full year revenue guidance.Q3 adjusted earnings per share $0.08.Q3 gaap earnings per share $0.15.Q3 revenue $84.6 million versus i/b/e/s view $80.1 million.Q3 earnings per share view $0.08 -- Thomson Reuters I/B/E/S.Sees Q4 2017 revenue $87 million to $88 million.Sees FY 2017 revenue $320.6 million to $321.6 million.Says an additional increase of $10 million to share repurchase program was authorized by MiMedx board​.Says GAAP EPS(FD) for 2017 projected to be in range of $0.31 to $0.32​.Says ‍adjusted EPS(FD) for 2017 projected to be in range of $0.31 to $0.32​.Q4 earnings per share view $0.09, revenue view $83.1 million -- Thomson Reuters I/B/E/S.FY 2017 earnings per share view $0.31, revenue view $312.2 million -- Thomson Reuters I/B/E/S.  Full Article

MiMedx says FDA approves investigational new drug clinical trial for osteoarthritis of knee
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - MiMedx Group Inc : :MiMedx notified by FDA that it can proceed with phase 2B investigational new drug clinical trial for osteoarthritis of the knee.MiMedx Group Inc - ‍been notified by FDA that its investigational new drug (IND) phase 2B clinical study for osteoarthritis of knee may proceed​.MiMedx Group Inc - ‍phase 2b trial will enroll approximately 318 patients and company expects patient enrollment to commence in next quarter​.Mimedx group inc - ‍trial will enroll approximately 318 patients and company expects patient enrollment to commence in next quarter​.MiMedx Group- clinical trial of phase 2B trial to enroll approximately 318 patients and co expects patient enrollment to commence in next quarter​.MiMedx group - ‍ believe results of co's BLA clinical trials for Amniofix injectable and safety profile will demand a price per dose of $1,000 or more​.  Full Article

Mimedx Group Inc preliminary Q3 revenue $84.6 million
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Mimedx Group Inc ::Announces third quarter revenues of $84.6 million exceeds guidance by more than 5 percent.Says preliminary Q3 revenue $84.6 million versus I/B/E/S view $79.3 million .  Full Article

MiMedx board authorizes $10 mln increase to share repurchase program
Monday, 9 Oct 2017 

Oct 9 (Reuters) - MiMedx Group Inc :MiMedx board of directors authorizes $10 million increase to the company's share repurchase program.MiMedx - ‍action by board authorizing additional share repurchase brings total authorized to $110 million since share repurchase program commenced May 2014​.MiMedx - ‍in light of short seller actions, board believes stock repurchases continue to be "extremely positive investment" for MiMedx​.  Full Article

MiMedx Group updates on co's patent infringement lawsuit
Monday, 18 Sep 2017 

Sept 18 (Reuters) - MiMedx Group Inc ::Company prevailed in its patent infringement lawsuit against Musculoskeletal Transplant Foundation Inc​.District court ordered co, Medline to submit pre-trial submissions later this month; case will then be assigned a trial date​.  Full Article

BRIEF-MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln

* MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION